Open AccessReduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Author(s) -
Shawn J. Kile,
William Au,
Carol Parise,
Jaideep Sohi,
Tracy L. Yarbrough,
Alan Czeszynski,
Ken Johnson,
Dan Redline,
Tammy Donnel,
Andrea Hankins,
Kimberley Rose
Publication year - 2020
Publication title -
american journal of alzheimer s disease and other dementias®
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.653
H-Index - 60
eISSN - 1938-2731
pISSN - 1533-3175
DOI - 10.1177/1533317519899800
Subject(s) - amyloid (mycology) , cognitive impairment , retinal , positron emission tomography , medicine , retina , central nervous system , β amyloid , standardized uptake value , pathology , ophthalmology , alzheimer's disease , nuclear medicine , psychology , disease , neuroscience
Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom